Outstanding clinical performance and excellent
Long-term patient results.
Outstanding Clinical Performance
Excellent Long-Term Patient Results.
Mode of Action
With balloon dilatation, the injuries to the arterial wall initiate an inflammatory reaction with an excretion of growth factors which trigger the onset of cell division and smooth muscle cell migration.
• De-novo lesions
• Restenosis after realisation of balloon and /or stent PTA
• Pre-and post-dilatation in case of peripheral stent implantation
- Excellent pushability
- Targeted drug delivery into the vascular wall
- Single shot, short-term Paclitaxel delivery for long-term vessel patency
- Homogeneous and complete polymer-free drug release
- Low profile tip and balloon design for reduced friction and advanced crossing performance
- Homogeneous drug delivery
- Effectively inhibiting proliferation
Paclitaxel prevents restenosis by stabilizing microtubal formation and thus prevents the cells going through the phases of replication, resulting in the inhibition of cell division.
|Paclitaxel Drug Dose||3.0-3.5 µg/mm2|
|Balloon Diameter||2.0 mm to 10 mm|
|Guiding Catheter Profile||5F, 6F, 7F|
|Balloon Lenght||15, 20, 40, 60, 80, 100, 120, 150, 220 mm|
|Balloon Fold Configuration||2.0 to 4.0 mm: 3 folds; 4.0 to 10 mm: 6 folds|
|Radiopacity||Pt-Ir Ring marker|
|Guidewire Compatible||0,014”, 0,018”, 0,025”|
|Catheter Design||Over the wire (OTW)|
|Catheter Lenght||80cm, 90cm, 120cm, 135 cm, 150 cm|
|Structure of the Catheter||PA/PEBAX|